Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Inclusion Criteria: * Has had prior laboratory-confirmed SARS-CoV-2 infection as determined by an approved polymerase chain reaction (PCR) or an approved antigen test of any specimen * Has had a recent (within a week) negative SARS-CoV-2 test (an approved PCR or antigen test) * Has had at least moderate or severe post-COVID-19 pulmonary symptoms for at least 3 months which have resulted in reduced physical functioning compared to pre-COVID-19 status * Willing to follow contraception guidelines Exclusion Criteria: * Clinically improving pulmonary status over the month prior to screening * Undergone a previous stem cell infusion unrelated to this trial * Pregnant or breast feeding or planning for either during the study * Suspected uncontrolled active bacterial, fungal, viral, or other infection * Any significant medical condition, laboratory value or other illness that in the investigator's opinion would interfere or prevent safe participation in the study * History of a splenectomy, lung transplant or lung lobectomy * Concurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable)